Neurocrine Biosciences Company Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.

The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia.

Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.

The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences, Inc.

Country	United States
Founded	1992
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	1,800
CEO	Kyle Gano

Contact Details

Address: 12780 El Camino Real San Diego, Delaware 92130 United States
Phone	858 617 7600
Website	neurocrine.com

Stock Details

Ticker Symbol	0K6R
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US64125C1099
SIC Code	2836

Key Executives

Name	Position
Kyle Gano	Chief Executive Officer
Matthew Abernethy	Chief Financial Officer
Jane Sorensen	Head of Investor Relations